01—Abstract
Summary
Summary of the 10-K filed February 5, 2024. Cited figures are marked; the original filing is the authoritative source.
Regeneron's FY2023 results show revenue of $13.12 billiona, up about 8% from $12.17 billion in 2022, but net income fell 9% to $3.95 billion and diluted EPS dropped to $34.77 from $38.22.
The decline reflects higher operating expenses, which rose 22% to $9.07 billionb, driven by R&D up 24% to $4.44 billion and SG&A up 24% to $2.63 billion. Lower income tax expense (effective rate 5.9% versus 10.7%) partly cushioned the drop. Interest income surged to $496 million on higher rates, helping offset unrealized losses on equity securities.
The core commercial concern is concentration and erosion in the ophthalmology franchise. U.S. EYLEA and the newly launched EYLEA HD fell 6%c combined, and EYLEA's regulatory exclusivity expires May 17, 2024, opening the door to biosimilars. Management stated EYLEA HD's uptake is needed to offset EYLEA erosion, and that the degree of offset is uncertain.
Dupixent, co-commercialized with Sanofi, is the main growth engine: Regeneron's share of antibody profits rose to $3.14 billiond from $2.08 billion, and Dupixent's COPD filing and CSU complete response letter shape its near-term pipeline. Libtayo's global sales grew to $863 million. Balance sheet strength is substantial, with $16.2 billion in cash and marketable securities against $2.7 billion of debt and finance lease obligations.
The company repurchased $2.2 billion of stock in 2023 and has $1.53 billion remaining under its authorization. Risks to note include a heavy reliance on two U.S. distributors (76% of gross product revenue), ongoing DOJ and False Claims Act matters tied to EYLEA and other products, and Amgen and biosimilar patent litigation. Capital expenditures are guided to $825 million to $950 million in 2024.
02—Key points
Key Highlights
- Total revenue rose 7.8% to $13.12 billion, but net income fell 8.9% to $3.95 billion and diluted EPS fell 9.1% to $34.77.
- Operating expenses grew 22% to $9.07 billion, led by R&D (+24% to $4.44 billion) and SG&A (+24% to $2.63 billion), compressing operating income to $4.05 billion from $4.74 billion.
- EYLEA franchise (EYLEA HD and EYLEA, U.S.) was $5.89 billion, down 6%, and represented 45% of total revenue; EYLEA's regulatory exclusivity ends May 17, 2024, raising biosimilar competition risk.
- Dupixent drove growth: Regeneron's share of antibody collaboration profits rose 51% to $3.14 billion, with the company's profit share rising to 26% of Dupixent and Kevzara net sales.
- Libtayo global net sales grew 93% to $863 million after Regeneron took full worldwide rights in July 2022; Sanofi's 11% royalty runs through March 2034.
- Strong liquidity: $16.2 billion in cash and marketable securities against roughly $2.7 billion of debt and finance lease obligations; $2.2 billion of buybacks in 2023 with $1.53 billion remaining authorization.
- Concentration and legal risk: two U.S. distributors accounted for 76% of gross product revenue, and the company faces DOJ False Claims Act and Anti-Kickback matters related to EYLEA and other products, plus Amgen and biosimilar patent litigation.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 5, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $13.12B$12.17B | +7.8% |
| R&D Expenses | $4.44B$3.59B | +23.6% |
| SG&A Expenses | $2.63B$2.12B | +24.4% |
| Operating Expenses | $9.07B$7.43B | +22.0% |
| Operating Income | $4.05B$4.74B | −14.6% |
| Interest Expense | $73.00M$59.40M | +22.9% |
| Net Income | $3.95B$4.34B | −8.9% |
| EPS (Basic) | $37.05$40.51 | −8.5% |
| EPS (Diluted) | $34.77$38.22 | −9.0% |
| Shares Outstanding (Basic) | 106.70M107.10M | −0.4% |
| Shares Outstanding (Diluted) | 113.70M113.50M | +0.2% |
05—Questions
Frequently Asked Questions
Why did net income decline in 2023 even though revenue grew?
Revenue rose $944 million, but operating expenses rose $1.64 billion. R&D increased $847 million and SG&A increased $515 million, mainly from higher headcount, Libtayo commercialization costs, and clinical development. Income tax expense fell to $246 million, which limited the decline, but operating income still dropped about 15%.
How much of Regeneron's revenue depends on EYLEA, and what happens after its exclusivity ends?
U.S. EYLEA and EYLEA HD represented 45% of 2023 total revenue. EYLEA's FDA regulatory exclusivity expires May 17, 2024, allowing biosimilar approvals. Management said EYLEA HD, launched in August 2023, may offset EYLEA declines, but the degree of offset is uncertain. The company also relies on Bayer for ex-U.S. EYLEA sales.
Is Dupixent a growing contributor to Regeneron's earnings?
Yes. Regeneron's share of antibody collaboration profits, mainly from Dupixent and Kevzara, rose to $3.14 billion in 2023 from $2.08 billion in 2022. Dupixent's U.S. net sales reached $8.86 billion. Pending COPD filings and CSU and other pipeline readouts could expand the franchise, but the CSU sBLA received a complete response letter requiring more efficacy data.
What are the main financial and legal risks an investor should watch?
Key risks include EYLEA biosimilar erosion, dependence on two U.S. distributors for 76% of gross product revenue, and ongoing DOJ and False Claims Act matters tied to EYLEA kickbacks and pricing reporting. The company also faces Amgen patent and antitrust litigation, Praluent-related claims, and manufacturing scrutiny after a 2023 FDA complete response letter tied to a third-party filler. Balance sheet leverage is modest, but cash flow from operations fell 8% to $4.59 billion.
06—Continue